

# Oskar Hansson

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/1661466/publications.pdf](https://exaly.com/author-pdf/1661466/publications.pdf)

Version: 2024-02-01

514  
papers

41,861  
citations

1718

104  
h-index

3945

177  
g-index

564  
all docs

564  
docs citations

564  
times ranked

29734  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. <i>Lancet Neurology</i> , The, 2006, 5, 228-234.	10.4	1,494
2	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	7.5	1,009
3	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	10.4	668
4	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. <i>Nature Medicine</i> , 2020, 26, 379-386.	31.0	643
5	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	7.5	640
6	Earliest accumulation of $\beta$ -amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214.	13.0	596
7	Cerebrospinal Fluid Levels of $\beta$ -Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. <i>Archives of General Psychiatry</i> , 2012, 69, 98.	12.3	554
8	Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease. <i>Neuron</i> , 2002, 33, 849-860.	8.2	553
9	CSF biomarkers of Alzheimer's disease concord with amyloid $\beta$ PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1470-1481.	0.8	468
10	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	10.4	464
11	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	9.2	455
12	Plasma $\beta$ -amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> , 2016, 6, 26801.	3.4	442
13	Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity. <i>Biological Psychiatry</i> , 2009, 66, 287-292.	1.3	436
14	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. <i>Archives of Neurology</i> , 2010, 67, 949.	4.5	407
15	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. <i>Archives of Neurology</i> , 2012, 69, 1445.	4.5	407
16	Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13924-13929.	7.2	407
17	Amyloid biomarkers in Alzheimer's disease. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 297-309.	8.8	404
18	Biomarkers for neurodegenerative diseases. <i>Nature Medicine</i> , 2021, 27, 954-963.	31.0	399

#	ARTICLE	IF	CITATIONS
19	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 573-586.	10.4	393
20	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016, 87, 1827-1835.	1.1	371
21	Blood-based NfL. <i>Neurology</i> , 2017, 88, 930-937.	1.1	369
22	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology</i> , The, 2022, 21, 66-77.	10.4	360
23	Four distinct trajectories of tau deposition identified in Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 871-881.	31.0	354
24	Impact of an Exercise Intervention on DNA Methylation in Skeletal Muscle From First-Degree Relatives of Patients With Type 2 Diabetes. <i>Diabetes</i> , 2012, 61, 3322-3332.	0.6	334
25	CSF A $\beta$ <sub>42</sub> /A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> /A $\beta$ <sub>38</sub> ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165.	3.7	329
26	Plasma tau levels in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 9.	6.2	328
27	Improving the Survival of Grafted Dopaminergic Neurons: A Review over Current Approaches. <i>Cell Transplantation</i> , 2000, 9, 179-195.	2.5	327
28	Advantages and disadvantages of the use of the CSF Amyloid $\beta$ (A $\beta$ ) <sub>42</sub> /40 ratio in the diagnosis of Alzheimer's Disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 34.	6.2	325
29	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid $\beta$ -Amyloid 42. <i>JAMA Neurology</i> , 2014, 71, 1282.	9.2	300
30	Discriminative Accuracy of [ <sup>18</sup> F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	7.5	298
31	Cerebrospinal fluid analysis detects cerebral amyloid- $\beta$ accumulation earlier than positron emission tomography. <i>Brain</i> , 2016, 139, 1226-1236.	7.7	292
32	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015, 85, 1240-1249.	1.1	288
33	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 2612.	13.0	283
34	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related $\beta$ -Amyloid Status. <i>JAMA Neurology</i> , 2019, 76, 1060.	9.2	282
35	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. <i>Nature Medicine</i> , 1999, 5, 97-100.	31.0	279
36	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1180-1190.	0.8	254

#	ARTICLE	IF	CITATIONS
37	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	10.4	254
38	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1683.	13.0	252
39	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.8	249
40	Prediction of Alzheimer's Disease Using the CSF A $\beta$ 42/A $\beta$ 40 Ratio in Patients with Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 316-320.	1.5	248
41	Evaluation of plasma A $\beta$ 240 and A $\beta$ 42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 357-367.	3.1	242
42	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	31.0	236
43	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019, 11, e11170.	7.0	228
44	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology</i> , The, 2021, 20, 739-752.	10.4	220
45	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016, 8, 1184-1196.	7.0	219
46	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	13.0	219
47	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2014, 9, 53.	10.8	216
48	Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 8727-8732.	7.2	215
49	Cerebrospinal fluid inflammatory markers in Parkinson's disease " Associations with depression, fatigue, and cognitive impairment. <i>Brain, Behavior, and Immunity</i> , 2013, 33, 183-189.	4.2	214
50	CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e30525.	2.5	209
51	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018, 91, e867-e877.	1.1	207
52	Expression of TGF- $\beta$ 2 isoforms, TGF- $\beta$ 2 receptors, and SMAD molecules at different stages of human glioma. <i>International Journal of Cancer</i> , 2000, 89, 251-258.	5.2	206
53	A $\beta$ 2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387.	10.5	202
54	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 197-210.	2.8	201

#	ARTICLE	IF	CITATIONS
55	Plasma GFAP is an early marker of amyloid- $\beta$ but not tau pathology in Alzheimer's disease. <i>Brain</i> , 2021, 144, 3505-3516.	7.7	198
56	Mitochondrial Control of Acute Glutamate Excitotoxicity in Cultured Cerebellar Granule Cells. <i>Journal of Neuroscience</i> , 1998, 18, 10277-10286.	3.7	197
57	Associations between tau, A $\beta$ , and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , 2019, 92, e601-e612.	1.1	196
58	$\beta$ -amyloid Peptides and Amyloid Plaques in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2015, 12, 3-11.	4.5	195
59	Head-to-Head Comparison of 8 Plasma Amyloid- $\beta$ 42/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1375.	9.2	195
60	Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. <i>Archives of Neurology</i> , 2008, 65, 1102-7.	4.5	193
61	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 347.	13.0	185
62	CSF biomarkers predict a more malignant outcome in Alzheimer disease. <i>Neurology</i> , 2010, 74, 1531-1537.	1.1	182
63	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. <i>Brain Research</i> , 2010, 1362, 13-22.	2.2	180
64	Non-Motor Symptoms in Patients with Parkinson's Disease – Correlations with Inflammatory Cytokines in Serum. <i>PLoS ONE</i> , 2012, 7, e47387.	2.5	180
65	Fluid biomarkers in Alzheimer's disease – current concepts. <i>Molecular Neurodegeneration</i> , 2013, 8, 20.	10.8	180
66	Systematic development of small molecules to inhibit specific microscopic steps of A $\beta$ 42 aggregation in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E200-E208.	7.2	180
67	CSF biomarkers and clinical progression of Parkinson disease. <i>Neurology</i> , 2015, 84, 57-63.	1.1	178
68	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 149.	9.2	176
69	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.8	174
70	Levels of cerebrospinal fluid $\alpha$ -synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 25.	6.2	169
71	Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. <i>Brain</i> , 2020, 143, 1233-1248.	7.7	164
72	<sup>18</sup> F-AV-451 and CSF Tau and P-tau as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	7.0	156

#	ARTICLE	IF	CITATIONS
73	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012, 78, 468-476.	1.1	154
74	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. <i>Neurobiology of Aging</i> , 2017, 51, 104-112.	3.1	154
75	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3234-3241.	7.7	150
76	<sup>18</sup> F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. <i>Brain</i> , 2016, 139, 2372-2379.	7.7	149
77	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. <i>Brain</i> , 2017, 140, 2286-2294.	7.7	149
78	Staging $\beta$ -Amyloid Pathology With Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , 2019, 76, 1319.	9.2	149
79	Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 118-124.	1.5	148
80	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 961.	9.2	148
81	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 169.	5.2	146
82	Amyloid blood biomarker detects Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2018, 10, .	7.0	145
83	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. <i>European Journal of Neuroscience</i> , 2001, 14, 1492-1504.	2.6	140
84	Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis. <i>Neurology</i> , 2013, 80, 829-838.	1.1	138
85	Cerebrospinal fluid neurogranin and $\alpha$ 4 as biomarkers of Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 12-20.	3.7	137
86	Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 898-905.	4.0	136
87	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. <i>JAMA Neurology</i> , 2020, 77, 955.	9.2	136
88	Association of Cerebral Amyloid $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.2	133
89	Prevalence of amyloid $\beta$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	5.4	132
90	Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 366.	4.5	131

#	ARTICLE	IF	CITATIONS
91	Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. <i>Lancet Neurology</i> , 2022, 21, 726-734.	10.4	130
92	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 279-296.	7.8	128
93	Low CSF Levels of Both $\beta$ -Synuclein and the $\beta$ -Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. <i>PLoS ONE</i> , 2013, 8, e53250.	2.5	123
94	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys $A\beta$ (1-42), pTau and tTau CSF immunoassays. <i>Scientific Reports</i> , 2019, 9, 19024.	3.4	123
95	Kinetic fingerprints differentiate the mechanisms of action of anti- $A\beta$ antibodies. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 1125-1133.	8.4	123
96	Untangling the association of amyloid- $\beta$ and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324.	7.7	123
97	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14408.	7.0	122
98	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	6.2	121
99	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. <i>Acta Neuropathologica</i> , 2014, 127, 633-643.	7.8	120
100	Evaluating Amyloid- $\beta$ Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e66381.	2.5	119
101	Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. <i>Brain Research</i> , 2003, 970, 47-57.	2.2	117
102	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 68.	6.2	117
103	Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches—Twenty years of research and development. <i>Forensic Science International: Genetics</i> , 2015, 18, 100-117.	3.1	116
104	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. <i>Brain</i> , 2017, 140, 98-117.	7.7	116
105	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021, 12, 3555.	13.0	115
106	Increased basal ganglia binding of $^{18}F$ -AV-1451 in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2017, 32, 108-114.	4.0	111
107	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1119-1128.	2.7	110
108	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 403-410.	2.7	109

#	ARTICLE	IF	CITATIONS
109	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	7.7	109
110	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2015, 85, 1834-1842.	1.1	109
111	LifeTime and improving European healthcare through cell-based interceptive medicine. <i>Nature</i> , 2020, 587, 377-386.	28.1	108
112	Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 45-53.	2.7	106
113	Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e29868.	2.5	106
114	Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 17.	6.2	105
115	Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. <i>NeuroMolecular Medicine</i> , 2011, 13, 151-159.	3.4	104
116	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 40.	6.2	104
117	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. <i>Scientific Reports</i> , 2018, 8, 13276.	3.4	104
118	In vivo retention of <sup>18</sup> F-AV-1451 in corticobasal syndrome. <i>Neurology</i> , 2017, 89, 845-853.	1.1	103
119	Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. <i>Human Brain Mapping</i> , 2019, 40, 2529-2545.	3.7	103
120	Apathy and anxiety are early markers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 85, 74-82.	3.1	103
121	Soluble TNF receptors are associated with A $\beta$ metabolism and conversion to dementia in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 1877-1884.	3.1	101
122	Plasma amyloid $\beta$ and risk of Alzheimer's disease in the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2015, 11, 249.	0.8	101
123	Relationship between cortical iron and tau aggregation in Alzheimer's disease. <i>Brain</i> , 2020, 143, 1341-1349.	7.7	101
124	A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of A $\beta$ <sup>38</sup> , A $\beta$ <sup>40</sup> , and A $\beta$ <sup>42</sup> in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1021-1032.	2.7	100
125	Clinical validity of cerebrospinal fluid A $\beta$ <sup>42</sup> , tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 196-213.	3.1	100
126	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. <i>Archives of Neurology</i> , 2010, 67, 217-23.	4.5	99



#	ARTICLE	IF	CITATIONS
127	Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients. <i>European Neurology</i> , 2010, 63, 326-330.	1.4	99
128	Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. <i>Neurobiology of Aging</i> , 2010, 31, 215-223.	3.1	97
129	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. <i>JAMA Neurology</i> , 2017, 74, 1492.	9.2	97
130	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.2	97
131	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.1	96
132	A $\beta$ 40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease. <i>PLoS ONE</i> , 2010, 5, e15725.	2.5	96
133	Amyloid- $\beta$ 2 Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 171-176.	2.7	95
134	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123.	11.6	94
135	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 58, 14-29.	3.1	93
136	Soluble P $\beta$ tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021, 13, e14022.	7.0	90
137	Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. <i>Brain Research</i> , 2000, 857, 20-29.	2.2	89
138	Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. <i>Brain</i> , 2018, 141, 2755-2771.	7.7	89
139	Validation of Plasma Amyloid- $\beta$ 42/40 for Detecting Alzheimer Disease Amyloid Plaques. <i>Neurology</i> , 2022, 98, .	1.1	89
140	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. <i>Frontiers in Neuroscience</i> , 2017, 11, 167.	2.9	87
141	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.8	87
142	Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, .	10.5	86
143	Patterns of Cell Death and Dopaminergic Neuron Survival in Intrastratial Nigral Grafts. <i>Experimental Neurology</i> , 1999, 160, 279-288.	4.1	85
144	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. <i>JAMA Psychiatry</i> , 2014, 71, 1183.	11.2	85

#	ARTICLE	IF	CITATIONS
145	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	10.4	85
146	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. <i>PLoS ONE</i> , 2015, 10, e0135458.	2.5	85
147	Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. <i>European Journal of Neuroscience</i> , 2001, 13, 206-210.	2.6	84
148	An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2015, 14, 654-663.	3.8	84
149	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017, 59, 1-9.	3.1	84
150	Predicting diagnosis and cognition with <sup>18</sup> F-AV-1451 tau PET and structural MRI in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 570-580.	0.8	84
151	Correlation of In Vivo [ <sup>18</sup> F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. <i>JAMA Neurology</i> , 2019, 76, 310.	9.2	84
152	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , 2022, 18, 1484-1497.	0.8	84
153	Pleiotropic Effects of GIP on Islet Function Involve Osteopontin. <i>Diabetes</i> , 2011, 60, 2424-2433.	0.6	83
154	Comparing <sup>18</sup> F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.1	83
155	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2140-2156.	6.4	83
156	Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons. <i>Experimental Neurology</i> , 2000, 164, 102-111.	4.1	80
157	The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , 2020, 94, e2233-e2244.	1.1	80
158	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 632.	9.2	80
159	Distinct cerebrospinal fluid amyloid $\beta$ peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 2.	10.8	79
160	Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease. <i>PLoS ONE</i> , 2009, 4, e6294.	2.5	79
161	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 20.	6.2	78
162	Reference measurement procedure for CSF amyloid beta ( $A\beta$ ) <sub>1-42</sub> and the CSF $A\beta$ <sub>1-42</sub> / $A\beta$ <sub>1-40</sub> ratio: a cross-validation study against amyloid PET. <i>Journal of Neurochemistry</i> , 2016, 139, 651-658.		78

#	ARTICLE	IF	CITATIONS
163	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 76.	4.9	78
164	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , 2021, 144, 2771-2783.	7.7	78
165	Factors associated with fear of falling in people with Parkinson's disease. <i>BMC Neurology</i> , 2014, 14, 19.	1.8	77
166	Increased midlife triglycerides predict brain $\beta$ -amyloid and tau pathology 20 years later. <i>Neurology</i> , 2018, 90, e73-e81.	1.1	76
167	Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance. <i>Diabetes</i> , 2013, 62, 2088-2094.	0.6	75
168	Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson's Disease Dementia. <i>PLoS ONE</i> , 2015, 10, e0141825.	2.5	75
169	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2011, 3, 1.	3.5	73
170	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. <i>PLoS ONE</i> , 2012, 7, e38639.	2.5	73
171	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 335-344.	0.8	73
172	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1405-1412.	2.7	72
173	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 226-235.	3.7	72
174	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma $A\beta_{42}/A\beta_{40}$ and $\tau$ . <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.8	72
175	Exploring causality of the association between smoking and Parkinson's disease. <i>International Journal of Epidemiology</i> , 2019, 48, 912-925.	2.0	70
176	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 165-173.	3.1	69
177	Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1223-1230.	2.7	68
178	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 537-546.	2.7	68
179	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> , 2020, 143, 650-660.	7.7	68
180	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2012, 119, 789-797.	2.8	67

#	ARTICLE	IF	CITATIONS
181	Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding. <i>Magnetic Resonance in Medicine</i> , 2020, 84, 1605-1623.	3.0	67
182	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. <i>Nature Communications</i> , 2020, 11, 619.	13.0	67
183	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 1729-1737.	2.7	66
184	Myo-inositol changes precede amyloid pathology and relate to <i>APOE</i> genotype in Alzheimer disease. <i>Neurology</i> , 2016, 86, 1754-1761.	1.1	66
185	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 149.	9.2	66
186	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021, 144, 2826-2836.	7.7	65
187	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. <i>Brain</i> , 2020, 143, 3805-3815.	7.7	65
188	Extensive changes in the transcriptional profile of human adipose tissue including genes involved in oxidative phosphorylation after a 6-month exercise intervention. <i>Acta Physiologica</i> , 2014, 211, 188-200.	3.8	62
189	Low <i>IL-8</i> is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 269-278.	4.5	62
190	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 281.	2.9	62
191	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. <i>Acta Neuropathologica</i> , 2017, 133, 149-151.	7.8	61
192	Head-to-head comparison of tau positron emission tomography tracers [ <sup>18</sup> F]flortaucipir and [ <sup>18</sup> F]RO948. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 342-354.	6.4	61
193	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. <i>Journal of Proteome Research</i> , 2014, 13, 1077-1087.	3.8	60
194	Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid A $\beta$ <sub>42</sub> and the Ratios of A $\beta$ <sub>2</sub> Isoforms Using Low Protein Binding Tubes. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1121-1132.	2.7	60
195	Elecsys <sup>®</sup> Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , 2019, 72, 30-38.	1.9	60
196	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021, 97, e1681-e1694.	1.1	60
197	<sup>18</sup> F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. <i>Scientific Reports</i> , 2018, 8, 4717.	3.4	59
198	Electroencephalogram Variability in Dementia with Lewy Bodies, Alzheimer's Disease and Controls. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 284-290.	1.5	58

#	ARTICLE	IF	CITATIONS
199	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
200	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma $\beta$ -tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	7.0	58
201	Prediction of Falls and/or Near Falls in People with Mild Parkinson's Disease. <i>PLoS ONE</i> , 2015, 10, e0117018.	2.5	57
202	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <i>ELife</i> , 2019, 8, .	6.1	57
203	Greater tau load and reduced cortical thickness in APOE $\epsilon$ 4-negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 77.	6.2	56
204	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e193-e202.	1.1	54
205	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2021, 34, 266-274.	3.7	54
206	Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. <i>Journal of Neurochemistry</i> , 2001, 78, 694-703.	3.9	53
207	Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. <i>Psychoneuroendocrinology</i> , 2013, 38, 853-862.	2.7	53
208	Modeling Strategies for Quantification of In Vivo $^{18}$ F-AV-1451 Binding in Patients with Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2017, 58, 623-631.	5.1	53
209	A Case of XXXXY Sex Chromosome Anomaly with Autoradiographic Studies. <i>Cytogenetic and Genome Research</i> , 1963, 2, 208-231.	1.0	52
210	Evolution of $A\beta$ 42 and $A\beta$ 40 levels and $A\beta$ 42/ $A\beta$ 40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 205-208.	3.3	52
211	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1599-1608.	3.1	52
212	Cerebral white matter lesions " associations with $A\beta$ 2 isoforms and amyloid PET. <i>Scientific Reports</i> , 2016, 6, 20709.	3.4	52
213	Trace DNA collection "Performance of minitape and three different swabs. <i>Forensic Science International: Genetics Supplement Series</i> , 2009, 2, 189-190.	0.3	51
214	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 82.	6.2	51
215	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid $\beta$ 2 and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582.	0.8	51
216	Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 625-636.	2.7	50

#	ARTICLE	IF	CITATIONS
217	NG2 cells, a new trail for Alzheimer's disease mechanisms?. <i>Acta Neuropathologica Communications</i> , 2013, 1, 7.	5.2	50
218	MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?. <i>American Journal of Neuroradiology</i> , 2017, 38, 1737-1741.	2.4	50
219	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. <i>BMC Neurology</i> , 2020, 20, 10.	1.8	50
220	Assessing risk for preclinical $\beta$ -amyloid pathology with <i>APOE</i> , cognitive, and demographic information. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 76-84.	2.4	49
221	Engineered antibodies: new possibilities for brain PET?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2848-2858.	6.4	49
222	Accurate risk estimation of $\beta$ -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019, 15, 194-204.	0.8	49
223	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. <i>Neurobiology of Disease</i> , 2020, 139, 104831.	4.5	49
224	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 26.	6.2	49
225	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2022, 98, .	1.1	49
226	Evaluation of Plasma $\beta$ as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 231-238.	2.7	48
227	Increased amyloidogenic APP processing in APOE $\epsilon$ 4-negative individuals with cerebral $\beta$ -amyloidosis. <i>Nature Communications</i> , 2016, 7, 10918.	13.0	48
228	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. <i>BMC Neurology</i> , 2014, 14, 64.	1.8	46
229	Autocatalytic amplification of Alzheimer-associated $A\beta$ 42 peptide aggregation in human cerebrospinal fluid. <i>Communications Biology</i> , 2019, 2, 365.	4.5	46
230	Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia. <i>Annals of Neurology</i> , 2020, 87, 52-62.	5.4	46
231	The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 192-198.	2.7	45
232	Evaluation of the Cerebrospinal Fluid Amyloid- $\beta$ 1-42/ $\beta$ 1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 36, 99-110.	1.5	45
233	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e81989.	2.5	45
234	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	3.4	45

#	ARTICLE	IF	CITATIONS
235	Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study. <i>Experimental Gerontology</i> , 2012, 47, 179-182.	2.8	44
236	Soluble amyloid precursor protein $\hat{\pm}$ and $\hat{\imath}^2$ in CSF in Alzheimer's disease. <i>Brain Research</i> , 2013, 1513, 117-126.	2.2	43
237	The A4 study: $\hat{\imath}^2$ amyloid and cognition in 4432 cognitively unimpaired adults. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 776-785.	3.7	43
238	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2121-2139.	6.4	43
239	Expression of Phosphofructokinase in Skeletal Muscle Is Influenced by Genetic Variation and Associated With Insulin Sensitivity. <i>Diabetes</i> , 2014, 63, 1154-1165.	0.6	41
240	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2295-2305.	6.4	41
241	FK506 and Cyclosporin A Enhance the Survival of Cultured and Grafted Rat Embryonic Dopamine Neurons. <i>Experimental Neurology</i> , 2000, 164, 94-101.	4.1	40
242	Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy. <i>PLoS ONE</i> , 2013, 8, e62354.	2.5	40
243	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinson's Disease</i> , 2019, 5, 7.	5.4	40
244	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. <i>European Journal of Neuroscience</i> , 2001, 14, 1425-1435.	2.6	39
245	Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. <i>Psychiatry Research - Neuroimaging</i> , 2018, 275, 5-13.	1.8	39
246	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. <i>Cerebral Cortex</i> , 2019, 29, 2173-2182.	3.0	39
247	CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2009, 30, 1265-1271.	3.1	38
248	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 1058-1066.	2.7	38
249	Towards a unified protocol for handling of CSF before $\hat{\imath}^2$ -amyloid measurements. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 63.	6.2	38
250	Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 450, 56-59.	2.1	37
251	Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 673-679.	2.7	37
252	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. <i>Neuroradiology</i> , 2015, 57, 1079-1091.	2.2	37

#	ARTICLE	IF	CITATIONS
253	Chapter 10 Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. <i>Progress in Brain Research</i> , 2000, 127, 203-231.	1.4	36
254	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , 2020, 11, 6252.	13.0	36
255	No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e50237.	2.5	36
256	Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. <i>Acta Neuropathologica Communications</i> , 2022, 10, 3.	5.2	36
257	Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia. <i>Experimental Brain Research</i> , 2004, 154, 442-449.	1.5	35
258	Preclinical Amyloid- $\beta^2$ and Axonal Degeneration Pathology in Delirium. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 371-379.	2.7	35
259	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. <i>PLoS ONE</i> , 2016, 11, e0157755.	2.5	35
260	Diagnostic Power of 24S-Hydroxycholesterol in Cerebrospinal Fluid: Candidate Marker of Brain Health. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 739-747.	2.7	34
261	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative diseases. <i>EuPA Open Proteomics</i> , 2015, 8, 137-143.	2.5	34
262	The clinical significance of 10-m walk test standardizations in Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1829-1835.	3.7	34
263	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 95, 143-153.	3.1	34
264	Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease. <i>Movement Disorders</i> , 2021, 36, 767-771.	4.0	34
265	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2097-2109.	6.4	34
266	Flunarizine improves the survival of grafted dopaminergic neurons. <i>Neuroscience</i> , 1999, 94, 17-20.	2.4	33
267	Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 638-647.	2.7	33
268	Increased Levels of Hyaluronic Acid in Cerebrospinal Fluid in Patients with Vascular Dementia. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1435-1441.	2.7	33
269	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. <i>Cerebrovascular Diseases Extra</i> , 2015, 5, 41-51.	1.5	33
270	$\beta$ -synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15226-15235.	7.2	33



#	ARTICLE	IF	CITATIONS
271	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2110-2120.	6.4	33
272	Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated $\beta$ -Amyloid Peptides. <i>Neurodegenerative Diseases</i> , 2008, 5, 268-276.	1.4	32
273	Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 314-319.	1.5	32
274	The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease. <i>PLoS ONE</i> , 2017, 12, e0185239.	2.5	32
275	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , 2020, 95, e3026-e3035.	1.1	31
276	Performance of $\beta$ -Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	31
277	CSF biomarkers for Alzheimer's pathology and the effect size of APOE $\epsilon$ 4. <i>Molecular Psychiatry</i> , 2014, 19, 148-149.	8.0	30
278	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 339-343.	2.7	30
279	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and $\beta$ Pathology in Non-demented Individuals. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 306.	3.5	30
280	Altered structural network organization in cognitively normal individuals with amyloid pathology. <i>Neurobiology of Aging</i> , 2018, 64, 15-24.	3.1	30
281	Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 87.	6.2	30
282	Method comparison study of the Elecsys $\beta$ -Amyloid (1 $\times$ 42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> , 2019, 72, 7-14.	1.9	30
283	Brain myoinositol as a potential marker of amyloid-related pathology. <i>Neurology</i> , 2019, 92, e395-e405.	1.1	30
284	A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 29.	6.2	29
285	Assessment of Global and Regional Diffusion Changes along White Matter Tracts in Parkinsonian Disorders by MR Tractography. <i>PLoS ONE</i> , 2013, 8, e66022.	2.5	29
286	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2018, 28, 3638-3649.	3.0	29
287	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 19.	6.2	29
288	A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1353-1363.	2.7	28

#	ARTICLE	IF	CITATIONS
289	Cognitive and functional changes associated with A $\beta$ pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	3.1	28
290	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. <i>Proteomics - Clinical Applications</i> , 2017, 11, 1700100.	1.6	28
291	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. <i>Cerebral Cortex</i> , 2018, 28, 340-349.	3.0	28
292	A $\beta$ -amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <i>Scientific Reports</i> , 2019, 9, 11180.	3.4	28
293	Association Between Apolipoprotein E $\epsilon$ 2 vs $\epsilon$ 4, Age, and A $\beta$ -Amyloid in Adults Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021, 78, 229.	9.2	28
294	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. <i>Scientific Reports</i> , 2021, 11, 1965.	3.4	28
295	Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease. <i>International Psychogeriatrics</i> , 2015, 27, 1401-1409.	1.0	27
296	Amyloid pathology in the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 64, 76-84.	3.1	27
297	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	3.7	27
298	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1661-1673.	3.7	27
299	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2245-2258.	6.4	27
300	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 403-411.	2.4	26
301	Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based prospective study. <i>Journal of Internal Medicine</i> , 2017, 282, 94-101.	6.1	26
302	18F-Flortaucipir in TDP-43 associated frontotemporal dementia. <i>Scientific Reports</i> , 2019, 9, 6082.	3.4	26
303	Tau PET Imaging in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 20S-26S.	5.1	26
304	Cystatin C Levels are Positively Correlated with both A $\beta$ 42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 471-478.	2.7	25
305	Differences in Survival between Patients with Dementia with Lewy Bodies and Patients with Alzheimer's Disease - Measured from a Fixed Cognitive Level. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 408-416.	1.5	25
306	External validation of a 3-step falls prediction model in mild Parkinson's disease. <i>Journal of Neurology</i> , 2016, 263, 2462-2469.	3.7	25

#	ARTICLE	IF	CITATIONS
307	Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process. <i>International Journal of Legal Medicine</i> , 2017, 131, 303-317.	2.3	25
308	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 2.	6.2	25
309	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE $\epsilon$ 4, sex and age. <i>Progress in Neurobiology</i> , 2021, 198, 101904.	5.8	25
310	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 259-265.	3.7	25
311	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1998-2008.	0.8	25
312	Prediction of Alzheimer's Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 556-563.	2.3	25
313	Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. <i>Biological Psychiatry</i> , 2011, 70, 145-151.	1.3	24
314	Characterisation of artefacts and drop-in events using STR-validator and single-cell analysis. <i>Forensic Science International: Genetics</i> , 2017, 30, 57-65.	3.1	24
315	Plasma $\tau$ NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. <i>Annals of Neurology</i> , 2020, 88, 878-892.	5.4	24
316	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster $A\beta$ -associated tau accumulation and cognitive decline. <i>Alzheimer's and Dementia</i> , 2022, 18, 103-115.	0.8	24
317	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. <i>Alzheimer's and Dementia</i> , 2022, 18, 2218-2233.	0.8	24
318	Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. <i>Alzheimer's and Dementia</i> , 2023, 19, 797-806.	0.8	24
319	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. <i>Neuroradiology</i> , 2018, 60, 247-254.	2.2	23
320	A fast analysis system for forensic DNA reference samples. <i>Forensic Science International: Genetics</i> , 2008, 2, 184-189.	3.1	22
321	Telomere length in blood and skeletal muscle in relation to measures of glycaemia and insulinaemia. <i>Diabetic Medicine</i> , 2012, 29, e377-81.	2.4	22
322	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 738-744.	2.7	22
323	Preclinical effects of APOE $\epsilon$ 4 on cerebrospinal fluid $A\beta$ 42 concentrations. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 87.	6.2	22
324	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. <i>Movement Disorders</i> , 2020, 35, 513-518.	4.0	22

#	ARTICLE	IF	CITATIONS
325	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	6.4	22
326	Association of $\beta$ -Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. <i>Neurology</i> , 2022, 98, .	1.1	22
327	First-Degree Relatives of Type 2 Diabetic Patients Have Reduced Expression of Genes Involved in Fatty Acid Metabolism in Skeletal Muscle. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1332-E1337.	3.7	21
328	Cerebral hypoperfusion is not associated with an increase in amyloid $\beta$ pathology in middle-aged or elderly people. <i>Alzheimer's and Dementia</i> , 2018, 14, 54-61.	0.8	21
329	Sex differences in off-target binding using tau positron emission tomography. <i>NeuroImage: Clinical</i> , 2021, 31, 102708.	2.8	21
330	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. <i>Biological Psychiatry</i> , 2022, 92, 34-43.	1.3	21
331	Grafting of Nigral Tissue Hibernated with Tirilazad Mesylate and Glial Cell Line-Derived Neurotrophic Factor. <i>Cell Transplantation</i> , 2000, 9, 577-584.	2.5	20
332	Cube Copying Test in Combination with rCBF or CSF $A\beta_{42}$ Predicts Development of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 544-552.	1.5	20
333	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 206-213.	2.7	20
334	Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 113-122.	1.4	20
335	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 63.	6.2	20
336	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. <i>Hippocampus</i> , 2017, 27, 653-667.	2.0	20
337	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from $\alpha$ -Synucleinopathies. <i>Radiology</i> , 2019, 293, 646-653.	7.4	20
338	Increased functional connectivity of thalamic subdivisions in patients with Parkinson's disease. <i>PLoS ONE</i> , 2019, 14, e0222002.	2.5	20
339	Time between milestone events in the Alzheimer's disease amyloid cascade. <i>NeuroImage</i> , 2021, 227, 117676.	4.3	20
340	Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12137.	2.4	20
341	Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 203-211.	1.5	19
342	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1039-1049.	2.7	19

#	ARTICLE	IF	CITATIONS
343	Cerebrospinal Fluid Levels of sAPP $\beta$ and sAPP $\gamma$ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-6.	2.0	19
344	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	1.9	19
345	Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. <i>Vascular Pharmacology</i> , 2020, 125-126, 106649.	2.2	19
346	No independent association between pulse wave velocity and dementia. <i>Journal of Hypertension</i> , 2017, 35, 2462-2467.	0.5	18
347	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. <i>Scientific Reports</i> , 2019, 9, 6079.	3.4	18
348	Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 67.	6.2	18
349	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, $\beta$ -synuclein, and total tau in combination with A $\beta$ (1-42)/A $\beta$ (1-40). <i>Alzheimer's Research and Therapy</i> , 2017, 9, 40.	6.2	17
350	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 9.	6.2	17
351	European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 538-549.	2.4	17
352	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE $\epsilon$ 4 carriers. <i>Scientific Reports</i> , 2020, 10, 8233.	3.4	17
353	Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort. <i>Movement Disorders</i> , 2020, 35, 1258-1263.	4.0	17
354	Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. <i>Acta Neuropathologica Communications</i> , 2021, 9, 19.	5.2	17
355	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 872-880.	1.9	17
356	The global Alzheimer's Association round robin study on plasma amyloid $\beta$ methods. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12242.	2.4	17
357	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 46.	6.2	17
358	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. <i>JAMA Neurology</i> , 2022, 79, 797.	9.2	17
359	Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 343-350.	2.7	16
360	STR-validator: An open source platform for validation and process control. <i>Forensic Science International: Genetics</i> , 2014, 13, 154-166.	3.1	16

#	ARTICLE	IF	CITATIONS
361	Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. <i>Neurodegenerative Diseases</i> , 2015, 15, 331-338.	1.4	16
362	Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0218561.	2.5	16
363	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019, 15, 1081-1103.	0.8	16
364	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. <i>Neurobiology of Disease</i> , 2020, 134, 104645.	4.5	16
365	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2183-2199.	6.4	16
366	Association of CSF A $\beta$ <sub>38</sub> Levels With Risk of Alzheimer Disease-Related Decline. <i>Neurology</i> , 2022, 98, .	1.1	16
367	Effects of APOE $\epsilon$ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 71, 81-90.	3.1	15
368	Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases. <i>NeuroImage: Clinical</i> , 2020, 28, 102386.	2.8	15
369	CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 156-163.	1.5	14
370	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 109.	6.2	14
371	Parkinson's disease: evolution of cognitive impairment and CSF A $\beta$ <sub>42</sub> profiles in a prospective longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 165-170.	1.9	14
372	Derivation and utility of an A $\beta$ -PET pathology accumulation index to estimate A $\beta$ load. <i>Neurology</i> , 2020, 95, e2834-e2844.	1.1	14
373	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 30.	6.2	14
374	Subtypes of Alzheimer's disease: questions, controversy, and meaning. <i>Trends in Neurosciences</i> , 2022, 45, 342-345.	8.8	14
375	A comparison of three automated DNA purification methods in Forensic casework. <i>Forensic Science International: Genetics Supplement Series</i> , 2008, 1, 76-77.	0.3	13
376	Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment. <i>Journal of Neural Transmission</i> , 2012, 119, 821-831.	2.8	13
377	A $\beta$ <sub>1-15/16</sub> as a Potential Diagnostic Marker in Neurodegenerative Diseases. <i>NeuroMolecular Medicine</i> , 2013, 15, 169-179.	3.4	13
378	Less pronounced response to exercise in healthy relatives to type 2 diabetic subjects compared with controls. <i>Journal of Applied Physiology</i> , 2015, 119, 953-960.	2.6	13

#	ARTICLE	IF	CITATIONS
379	Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes. <i>Journal of Parkinson's Disease</i> , 2022, 12, 571-584.	2.9	13
380	The protective gene dose effect of the <i>APOE</i> $\epsilon 2$ allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.8	13
381	Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation. <i>NeuroReport</i> , 1999, 10, 3347-3351.	1.2	12
382	Endogenous beta-cell CART regulates insulin secretion and transcription of beta-cell genes. <i>Molecular and Cellular Endocrinology</i> , 2017, 447, 52-60.	3.3	12
383	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. <i>Nutrition Research</i> , 2018, 60, 13-25.	2.9	12
384	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 158-165.	2.2	12
385	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1213-1220.	2.7	12
386	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 38.	6.2	12
387	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 23, 439-446.	1.9	11
388	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 15417.	3.4	11
389	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. <i>Pain</i> , 2020, 161, 2142-2154.	4.3	11
390	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. <i>Neurobiology of Aging</i> , 2020, 93, 1-15.	3.1	11
391	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2086-2096.	6.4	11
392	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. <i>Psychiatry Research - Neuroimaging</i> , 2021, 312, 111273.	1.8	11
393	Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents. <i>Experimental Neurology</i> , 2003, 183, 430-437.	4.1	10
394	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. <i>Clinical Endocrinology</i> , 2011, 75, 301-308.	2.5	10
395	Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?. <i>Lancet Neurology</i> , The, 2016, 15, 650-651.	10.4	10
396	Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 158.	6.2	10

#	ARTICLE	IF	CITATIONS
397	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. <i>NeuroImage: Clinical</i> , 2020, 27, 102310.	2.8	10
398	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 138.	6.2	10
399	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2259-2271.	6.4	10
400	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 1295-1305.	2.4	10
401	Flt3 ligand does not differentiate between Parkinsonian disorders. <i>Movement Disorders</i> , 2014, 29, 1319-1322.	4.0	9
402	The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls. <i>Quality of Life Research</i> , 2016, 25, 2571-2577.	3.1	9
403	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. <i>Clinical Mass Spectrometry</i> , 2019, 14, 74-82.	1.9	9
404	CSF placental growth factor is a novel candidate biomarker of frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 863-872.	3.7	9
405	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 327-332.	2.4	9
406	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. <i>Journal of Nuclear Medicine</i> , 2022, 63, 981-985.	5.1	9
407	Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?. <i>Brain</i> , 2018, 141, 1241-1244.	7.7	8
408	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 27-31.	2.7	8
409	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 683-691.	3.7	8
410	Tau pathology mediates age effects on medial temporal lobe structure. <i>Neurobiology of Aging</i> , 2022, 109, 135-144.	3.1	8
411	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. <i>Pain Reports</i> , 2022, 7, e988.	2.7	8
412	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders. <i>Movement Disorders</i> , 2022, 37, 993-1003.	4.0	8
413	A porous silicon immunoassay platform for fluorometric determination of $\beta$ -synuclein in human cerebrospinal fluid. <i>Mikrochimica Acta</i> , 2014, 181, 1143-1149.	5.1	7
414	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. <i>Scientific Reports</i> , 2019, 9, 2460.	3.4	7



#	ARTICLE	IF	CITATIONS
415	Components of gait in people with and without mild cognitive impairment. <i>Gait and Posture</i> , 2022, 93, 83-89.	1.4	7
416	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. <i>International Journal of Molecular Medicine</i> , 2007, 20, 233.	4.1	6
417	Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis. <i>Fluids and Barriers of the CNS</i> , 2015, 12, 22.	5.0	6
418	Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. <i>Journal of Parkinson's Disease</i> , 2016, 6, 99-108.	2.9	6
419	[18F]Flortaucipir distinguishes Alzheimer's disease from progressive supranuclear palsy pathology in a mixed-pathology case. <i>Acta Neuropathologica</i> , 2020, 139, 411-413.	7.8	6
420	Biomarker testing in MCI patients—deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.	6.2	6
421	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 19853.	3.4	6
422	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	6
423	Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. <i>Brain</i> , 2016, 139, e61-e61.	7.7	5
424	Cerebrospinal fluid A $\beta$ <sub>42</sub> /A $\beta$ <sub>40</sub> and A $\beta$ <sub>42</sub> /A $\beta$ <sub>38</sub> as biomarkers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 39, S28.	3.1	5
425	N-Terminal Prosomatostatin and Risk of Vascular Dementia. <i>Cerebrovascular Diseases</i> , 2017, 44, 259-265.	1.8	5
426	Psychometric testing of a Swedish version of the Apathy Evaluation Scale. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 477-484.	1.4	5
427	Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2223-2232.	4.4	5
428	Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. <i>Neuroradiology</i> , 2019, 61, 397-404.	2.2	5
429	High circulating levels of midregional proenkephalin A predict vascular dementia: a population-based prospective study. <i>Scientific Reports</i> , 2020, 10, 8027.	3.4	5
430	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1832-1842.	0.8	5
431	Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis. <i>Pain Practice</i> , 2021, , .	1.9	5
432	Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort. <i>Journal of Parkinson's Disease</i> , 2022, 12, 153-171.	2.9	5

#	ARTICLE	IF	CITATIONS
433	Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease. <i>European Journal of Neuroscience</i> , 2022, 55, 1859-1872.	2.6	5
434	Graft Survival. <i>Journal of Neurosurgery</i> , 1999, 90, 804-6.	1.7	4
435	Evaluation of GeneMapper <sup>®</sup> ID-X Mixture Analysis tool. <i>Forensic Science International: Genetics Supplement Series</i> , 2011, 3, e11-e12.	0.3	4
436	Increased CSF biomarkers of angiogenesis in Parkinson disease. <i>Neurology</i> , 2016, 86, 1747-1748.	1.1	4
437	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. <i>BMJ Open</i> , 2017, 7, e018177.	2.0	4
438	SCRT1 is a novel beta cell transcription factor with insulin regulatory properties. <i>Molecular and Cellular Endocrinology</i> , 2021, 521, 111107.	3.3	4
439	Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment. <i>European Radiology</i> , 2021, 31, 666-673.	4.5	4
440	Management of Alzheimer's disease takes a leap forward. <i>Lancet Neurology</i> , The, 2021, 20, 586-587.	10.4	4
441	Astrocytic function is associated with both amyloid- $\beta^2$ and tau pathology in non-demented APOE $\epsilon_4$ carriers. <i>Brain Communications</i> , 2022, 4, .	3.3	4
442	Brain activity and Alzheimer's disease: a complex relationship. <i>Brain</i> , 2016, 139, 2109-2110.	7.7	3
443	[IC <sup>02</sup> ]: ABNORMAL STRUCTURAL BRAIN CONNECTOME IN INDIVIDUALS WITH PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P7.	0.8	3
444	Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?. <i>BMJ Case Reports</i> , 2019, 12, e228177.	0.5	3
445	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2021, 18, 573-584.	1.5	3
446	Towards a universal cortical tau sampling mask. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	3
447	Evaluation of plasma A $\beta^{240}$ and A $\beta^{242}$ as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2010, 31, 541.	3.1	2
448	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. <i>Brain</i> , 2017, 140, e33-e33.	7.7	2
449	Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of Amyloid-Beta42 Aggregation in Alzheimer's Disease. <i>Biophysical Journal</i> , 2018, 114, 225a.	0.5	2
450	Forensic genetics: the basics. , 2020, , 1-53.		2

#	ARTICLE	IF	CITATIONS
451	Modeling patient-specific tau spreading patterns in Alzheimer's disease: Towards precision medicine. <i>Alzheimer's and Dementia</i> , 2020, 16, e040587.	0.8	2
452	The accumulation rate of tau aggregates is higher in females and younger individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, e043876.	0.8	2
453	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
454	Automatic data processing of reference DNA-profiles from FTA and non-FTA samples. <i>Forensic Science International: Genetics Supplement Series</i> , 2008, 1, 29-31.	0.3	1
455	Proteinase K challenged by a novel protease. <i>Forensic Science International: Genetics Supplement Series</i> , 2008, 1, 32-34.	0.3	1
456	Free open source software for internal validation of forensic STR typing kits. <i>Forensic Science International: Genetics Supplement Series</i> , 2013, 4, e300-e301.	0.3	1
457	Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease. <i>BMC Neurology</i> , 2015, 15, 8.	1.8	1
458	[P4-152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF $\beta$ -AMYLOID (1-42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1316.	0.8	1
459	P3-267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1178.	0.8	1
460	Genetic characterization of amyloid- $\beta$ and tau network spread. <i>Nature Medicine</i> , 2018, 24, 1790-1792.	31.0	1
461	P4-540: CSF PTAU <sub>17</sub> PERFORMS BETTER THAN PTAU <sub>181</sub> IN DETECTING ABNORMAL RETENTION OF <sup>18</sup> F-FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS. <i>Alzheimer's and Dementia</i> , 2019, 15, P1523.	0.8	1
462	Empirical characterization of DNA profiles. , 2020, , 55-88.		1
463	Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience. <i>European Radiology</i> , 2022, 32, 1127-1134.	4.5	1
464	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-15.	2.7	1
465	Plasma glial fibrillary acidic protein is an early and specific marker of amyloid- $\beta$ pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
466	Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta-amyloid, tau, neurodegeneration, and cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
467	P4-023: INCREASED LEVELS OF ANGIOGENIC FACTORS IN THE CEREBROSPINAL FLUID ARE ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PARKINSON'S DISEASE. , 2014, 10, P791-P791.		0
468	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE. , 2014, 10, P508-P508.		0

#	ARTICLE	IF	CITATIONS
469	P4â€³39: Earlyâ€•and Lateâ€•Onset Alzheimerâ€™S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]Fâ€•AVâ€•1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.8	0
470	Decreased ratio between Î²-amyloid 42 (AÎ²42) and AÎ²40 in cerebral spinal fluid is a better predictor of structural brain changes than AÎ²42 alone in cognitively normal elderly people. Neurobiology of Aging, 2016, 39, S17.	3.1	0
471	[ICâ€•Pâ€•123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AND AÎ²2 PATHOLOGY IN NONâ€•DEMENTED INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P94.	0.8	0
472	[P3â€•132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P985.	0.8	0
473	[P3â€•402]: PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE AND AMYLOID PATHOLOGY EXHIBIT SIGNIFICANT BRAIN ATROPHY, TAU PATHOLOGY AND MILD MEMORY DIFFICULTIES. Alzheimer's and Dementia, 2017, 13, P1117.	0.8	0
474	[P4â€•197]: EMERGING AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1340.	0.8	0
475	[P1â€•150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN <i>IL1RAP</i> AND ALZHEIMER'Sâ€•RELATED CSFâ€•BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P300.	0.8	0
476	[ICâ€•Pâ€•098]: ASSOCIATION BETWEEN CEREBROSPINAL FLUID AND PLASMA NEURODEGENERATION BIOMARKERS WITH BRAIN ATROPHY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P75.	0.8	0
477	[ICâ€•Pâ€•199]: [18]Fâ€•AVâ€•1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION. Alzheimer's and Dementia, 2017, 13, P146.	0.8	0
478	[P2â€•246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER'S DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.8	0
479	1947Biomarkers of microvascular endothelial dysfunction may predict dementia. European Heart Journal, 2017, 38, .	2.3	0
480	P4237N-terminal prosomatostatin predicts vascular dementia but not alzheimers disease. European Heart Journal, 2017, 38, .	2.3	0
481	P3â€•413: HETEROGENEOUS TAUâ€•PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1263.	0.8	0
482	ICâ€•Pâ€•224: HETEROGENEOUS TAUâ€•PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P182.	0.8	0
483	O2â€•09â€•02: A UNIFIED PREâ€•ANALYTICAL PROTOCOL FOR HANDLING OF CSF SAMPLES BEFORE ANALYSES OF AD BIOMARKER LEVELS. Alzheimer's and Dementia, 2018, 14, P641.	0.8	0
484	ICâ€•Pâ€•036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€•DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P39.	0.8	0
485	Primary fatty amides are potential plasma biomarkers for AD. Nature Reviews Neurology, 2019, 15, 498-499.	10.2	0
486	P4â€•531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO Î²â€•AMYLOID POSITIVITY. Alzheimer's and Dementia, 2019, 15, P1517.	0.8	0

#	ARTICLE	IF	CITATIONS
487	P1588 Beta-blocker therapy and risk of dementia: a population-based prospective study. <i>European Heart Journal</i> , 2019, 40, .	2.3	0
488	P4473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX A $\beta$ PEPTIDES IN HUMAN CEREBROSPINAL FLUID. <i>Alzheimer's and Dementia</i> , 2019, 15, P1492.	0.8	0
489	DT0104: DIAGNOSTIC PERFORMANCE OF [ <sup>18</sup> F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER $\epsilon$ 2 STUDY. <i>Alzheimer's and Dementia</i> , 2019, 15, P1485.	0.8	0
490	Allele drop-out and the stochastic threshold. , 2020, , 89-110.		0
491	Low-template DNA. , 2020, , 111-128.		0
492	A qualitative (semi-continuous) model: LRmix Studio. , 2020, , 153-179.		0
493	Investigative forensic genetics: SmartRank, CaseSolver and DNAmatch2. , 2020, , 339-383.		0
494	Improved performance of Elecsys CSF A $\beta$ measurement achieved using the simple, unified routine $\epsilon$ use protocol for CSF collection. <i>Alzheimer's and Dementia</i> , 2020, 16, e047394.	0.8	0
495	Cadmium and lead exposure and risk of dementia in a Swedish population-based cohort: The Malm $\epsilon$ Diet and Cancer Study. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
496	Genome editing (CRISPR-Cas9) to identify and characterise functional variants determining metformin response. , 2018, 13, .		0
497	Ability of tau $\epsilon$ PET, phospho $\epsilon$ tau217, NfL and cortical thickness to predict short $\epsilon$ term cognitive decline in early symptomatic Alzheimer $\epsilon$ ™s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
498	Unravelling drivers of age $\epsilon$ and beta $\epsilon$ amyloid $\epsilon$ related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
499	Establishment of updated biomarker cut $\epsilon$ off values for the second $\epsilon$ generation Elecsys $\beta$ 2 $\epsilon$ amyloid(1 $\epsilon$ 42), pTau and tTau CSF immunoassays. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
500	Soluble p $\epsilon$ tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
501	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinson $\epsilon$ ™s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
502	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
503	Impact of reduced injected dose on the quantification of [ <sup>18</sup> F]RO948 and [ <sup>18</sup> F]Flortaucipir PET for <i>in vivo</i> tau pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
504	Tau and synaptic biomarkers but not amyloid $\epsilon$ 2 are associated with cerebral perfusion in the Alzheimer $\epsilon$ ™s disease spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
505	Tau deposition is associated with grey matter network breakdown across different stages of the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
506	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
507	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
508	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P-tau181, P-tau217 and P-tau231 assays. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
509	Amyloid $\beta^2$ accumulation is independently related to executive function in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
510	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
511	The association between diet in mid-life and dementia incidence over a 20-year period. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
512	Potential drivers of age- and beta-amyloid-related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
513	[ <sup>18</sup> F]RO948 tau PET in bvFTD due to <i>C9orf72</i> and <i>GRN</i> mutations. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
514	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e055011.	0.8	0